An MCASE approach to the search of a cure for Parkinson's disease

BMC Pharmacology

Volumn 2, Issue , 2002, Pages

  Klopman, Gilles ^a,b   Sedykh, Aleksandr ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b KCI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,4,4A,9,10,10A OCTAHYDRO 7,8 DIHYDROXY 1 AZAPHENANTHRENE; 4 (3 PHOSPHONOALLYL) 2 PIPERAZINECARBOXYLIC ACID; ALPHA AMINO 5 (PHOSPHONOMETHYL)[1,1' BIPHENYL] 3 PROPANOIC ACID; BROMOCRIPTINE; DOPAMINE RECEPTOR AFFECTING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ELIPRODIL; IFENPRODIL; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; MONOAMINE OXIDASE INHIBITOR; N (3 HYDROXYPHENETHYL) N (PHENETHYL)PROPYLAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N,N BIS(3 HYDROXYPHENETHYL)PROPYLAMINE; PRECLAMOL; SDZ 220 581; UNCLASSIFIED DRUG;

ARTICLE; COMPUTER MODEL; COMPUTER PREDICTION; COMPUTER PROGRAM; CONTROLLED STUDY; DATA BASE; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; EQUIPMENT DESIGN; HUMAN; METHODOLOGY; PARKINSON DISEASE; SIDE EFFECT; STRUCTURE ACTIVITY RELATION;

EID: 2642570208     PISSN: 14712210     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2210-2-8     Document Type: Article

References (40)

1. Betarbet R, Sherer T, MacKenzie G, Garcia-Osuna M, Panov A, Greenamyre J: Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nature neuroscience 2000, 3:1301-1306
2. Goetz C: New Strategies with Dopaminergic Drugs: Modified Formulations of Levodopa and Novel Agonists. Experimental Neurology 1997, 144:17-20
3. Poewe W: Should treatment of Parkinson's disease be started with a dopamine agonist? Neurology 1998, 51:S21-S24
4. Bracco F: New drugs in the treatment of Parkinson's disease: an introduction. Advances in neurology 1996, 69:513-517
5. Magyar K, Szende B, Lengyel J, Tekes K: The pharmacology of B-type selective monoamine oxidase inhibitors; milestones in (-)-deprenyl research. Journal of Neural Transmission [Supplementum] 1996, 48:29-43
6. Berke J, Hyman S: Addiction, Dopamine, and the Molecular Mechanisms of Memory. Neuron 2000, 25:515-432
7. Greenamyre J: Glutamate-dopamine interactions in the basal ganglia: relationship to parkinson's disease. Journal of Neural Transmission [General Section] 1993, 91:255-269
8. Kalgutkar A, Castagnoli N, Testa B: Selective Inhibitors of Monoamine Oxidase (MAO-A and MAO-B) as Probes of its Catalytic Site and Mechanism. Medicinal Research Reviews 1995, 15:325-388
9. Mazouz F, Gueddari S, Burstein C, Mansuy D, Milcent R: 5-[4-(Benzyloxy) phenyl]-1,3,4-oxadiazol-2(3H)-one Derivatives and Related Analogues: New Reversible, Highly Potent, and Selective Monoamine Oxidase Type B Inhibitors. Journal of Medicinal Chemistry 1993, 36:1157-1167
10. Garcia C, Marco J, Fernandez-Alvarez E: Acetylenic and allenic derivatives of 2-(5-methoxy-l-methylindolyl)alkylamines as selective inhibitors of MAO-A and MAO-B. Journal of Neural Transmission [Supplementum] 1994, 41:287-290
11. Dostert P: Can our knowledge of monoamine oxidase (MAO) help in the design of better MAO inhibitors? Journal of Neural Transmission [Supplementum] 1994, 41:269-279
12. Seeman P, Ulpian C: Dopamine D1 and D2 receptor selectivities of agonists and antagonists. Advances in experimental medicine and biology 1988, 235:55-63
13. Seeman P, Watanabe M, Grigoriadis D, Tedesco J, George S, Svensson U, et al: Dopamine D2 Receptor Binding Sites for Agonists. A tetrahedral model. Molecular Pharmacology 1985, 28:391-399
14. van Vliet L, Tepper P, Dijkstra D, Damsma G, Wikstrom H, Pugsley T, et al: Affinity for Dopamine D2, D3, and D4 Receptors of 2-Aminotetralins. Relevance of D2 Agonist Binding for Determination of Receptor Subtype Selectivity. Journal of Medicinal Chemistry 1996, 39:4233-4237
15. Andersen P, Jansen J: Dopamine receptor agonists: selectivity and dopamine D1 receptor efficacy. European Journal of Pharmacology 1990, 188:335-347
16. Yamakura T, Shimoji K: Subunit- and Site-specific pharmacology of the NMDA receptor channel. Progress in Neurobiology 1999, 59:279-298
17. Schelkun R, Yuen P, Serpa K, Meltzer L, Wise L: Subtype-Selective N-Methyl-D-aspartate Receptor Antagonists: Benzimidazalone and Hydantoin as Phenol Replacements. Journal of Medicinal Chemistry 2000, 43:1892-1897
18. Wright J, Gregory T, Bigge C, Boxer P, Serpa K, Meltzer L, et al: Subtype-Selective N-Methyl-D-aspartate Receptor Antagonists: Synthesis and Biological Evaluation of 1-(Arylalkynyl)-4-benzylpiperidines. Journal of Medicinal Chemistry 1999, 42:2469-2477
19. Balsamini C, Bedini A, Spadoni G, Tarzia G, Tontini A, Balduini W, et al: 1-Aminocyclopropane-1-carboxylic acid derivatives as ligands at the glycine-binding site of the N-methyl-D-aspartate receptor. IL Farmaco 1998, 53:181-188
20. Klopman G: MULTICASE 1. A hierarchical computer automated structure evaluation program. Quantitative structure-activity relationships 1992, 11:176-184
21. Cheung N, O'Callaghan D, Ryan M, Dutton R, Wong M, Beart P: Structure-activity relationships of competitive NMDA receptor antagonists. European Journal of Pharmacology 1996, 313:159-162
22. Annan N, Silverman R: New Analogues of N-(2-Aminoethyl)-4-chlorobenzamide (Ro 16-6491). Some of the Most Potent Monoamine Oxidase-B Inactivators. Journal of Medicinal Chemistry 1993, 36:3968-3970
23. Moron J, Campillo M, Perez V, Unzeta M, Pardo L: Molecular Determinants of MAO Selectivity in a Series of Indolylmethylamine Derivatives: Biological Activities, 3D-QSAR/CoMFA Analysis, and Computational Simulation of Ligand Recognition. Journal of Medicinal Chemistry 2000, 43:1684-1691
24. White H, Heuser D, Joyner C, Batchelor J, Harfenist M: Selective Inhibitors of Monoamine Oxidase. 3. Structure-Activity Relationship of Tricyclics Bearing Imidazoline, Oxadiazole, or Tetrazole Groups. Journal of Medicinal Chemistry 1996, 39:1857-1863
25. Medvedev A, Veselovsky A, Shvedov V, Tikhonova O, Moskvitina T, Fedotova O, et al: Inhibition of Monoamine Oxidase by Pirlindole Analogues: 3D-QSAR and CoMFA Analysis. Journal of Chemical Information and Computer Sciences 1998, 38:1137-1144
26. Kneubiihier S, Thull U, Altomare C, Carta V, Gaillard P, Carrupt P, et al: Inhibition of Monoamine Oxidase-B by 5H-Indeno[l,2-c]pyridazines: Biological Activities, Quantitative Structure-Activity Relationships (QSARs) and 3D-QSARs. Journal of Medicinal Chemistry 1995, 38:3874-3883
27. Perez V, Marco J, Fernandez-Alvarez E, Unzeta M: Relevance of benzyloxy group in 2-indolyl methylamines in the selective MAO-B inhibition. British Journal of Pharmacology 1999, 127:869-876
28. Laube B, Hirai H, Sturgess M, Betz H, Kuhse J: Molecular determinants of Agonist Discrimination by NMDA Receptor Subunits: Analysis of the Glutamate Binding Site on the NR2B Subunit. Neuron 1997, 18:493-503
29. Ferrer-Montiel A, Sun W, Montal M: Molecular design of the N-methyl-D-aspartate receptor binding site for phencyclidine and dizocipine. Proc Natl Acad Sci USA 1995, 92:8021-8025
30. Wilcox R, Tseng T, Brusniak M-Y, Ginsburg B, Pearlman R, Teeter M, et al: CoMFA-Based Prediction of Agonist Affinities at Recombinant D1 vs. D2 Dopamine Receptors. Journal of Medicinal Chemistry 1998, 41:4385-4399
31. Hansson L, Waters N, Holm S, Sonesson C: On the Quantitative Structure-Activity Relationships of Meta-Substituted (S)-Phenylpiperidines, a Class of Preferential Dopamine D2 Autoreceptor Ligands: Modeling of Dopmaine Synthesis and release in Vivo by Means of partial Least Squares Regression. Journal of Medicinal Chemistry 1995, 38:3121-3131
32. Saiakhov R, Stefan L, Klopman G: Multiple computer-automated structure evaluation model of the plasma protein binding affinity of diverse drugs. Perspectives in Drug Discovery and Design 2000, 19:133-155
33. Klopman G, Dimayuga M, Talafous J: META. 1. A Program for the Evaluation of Metabolic Transformation of Chemicals. Journal of Chemical Information and Computer Sciences 1994, 34:1320-1325
34. Klopman G, Wang S: A computer Automated Structure Evaluation (CASE) Approach to Calculation of Partition Coefficient. Journal of Computational Chemistry 1991, 12:1025-1032
35. Matthews E, Contrera J: Highly Specific Method for Predicting the Carcinogenic Potential of Pharmaceuticals in Rodents Using Enhanced MCASE QSAR-ES Software. Regulatory Toxicology and Pharmacology 1998, 28:242-264
36. Rosenkranz H, Klopman G: The structure of the mutagenicity of chemicals in Salmonella typhimurium, The National Toxicology Program Data Base. Mutation Research 1990, 228:51-80
37. McAllister K: The competitive NMDA receptor antagonist SDZ 220-581 reverses haloperidol-induced catalepsy in rats. European Journal of Pharmacology 1996, 314:307-313
38. Fray M, Bull D, Carr C, Gautier E, Mowbray C, Stobie A: Structure-Activity Relationships of 1,4-Dihydro-(1H,4H)-quinoxaline-2,3-diones as N-Methyl-D-aspartate (Glycine Site) Receptor Antagonists. 1.Heterocyclic Substituted 5-Alkyl Derivatives. Journal of Medicinal Chemistry 2001, 44:1951-1962
39. Pinard E, Alanine A, Bourson A, Buettelmann B, Ramanjit G, Heitz MP, et al: Discovery of (R)-1-[2-Hydroxy-3-(4-hydroxy-phenyl)-propyl]- 4-(4-methyl-benzyl)-piperidin-4ol: A Noveri NR1/2B Subtype Selective NMDA Receptor Antagonist. Bioorganic & Medicinal Chemistry Letters 2001, 11:2173-2176
40. Baudy R, Fletcher H, Yardley J, Zaieska M, Bramlett D, Tasse R, et al: Design, Synthesis, SAR, and Biological Evaluation of Highly Potent Benzimidazole-Spaced Phosphono-a-Amino Acid Competitive NMDA Antagonists of the AP-6 Type. Journal of Medicinal Chemistry 2001, 44:1516-1529